
RESPIRI LIMITED

CHANGES TO THE RESPIRI BOARD

Melbourne, Australia: As foreshadowed in the Chairman's address at the AGM on 14 December 2017, Respiri Limited announces the appointment of two new directors today with medical device technology skills and Asian market expertise. Mr Mark Ziirsen and Mr Brendan Mason have been appointed directors of the Company.

The addition of Brendan Mason and Mark Ziirsen onto the Board provides the Company with medical device technology skills and relevant sector and market experience. The new directors have advised of approximately 14 years of combined senior experience with Cochlear Limited (ASX:COH), amongst other relevant roles, will be valuable in assisting the Company to complete development of its second generation AirSonea wheeze monitor.

Directors Leon L'Huillier and John Ribot-de-Bresac have brought forward their plans to retire from the Board and will retire from the Board as of today's date. Their retirement is timely given the results of the highly productive overseas series of meetings which have advanced key milestones around clinical and real world studies. The Company is in good shape.

Mr L'Huillier and Mr Ribot-de-Bresac joined the company in February 2014 and immediately addressed a myriad of significant challenges. The pivotal tasks for the Company were to develop a new product (software and hardware) with technological and financial rigour and build global potential partner relationships. As Chairman, Mr L'Huillier oversaw a substantial reduction in operating costs, achieved successful clinical studies and regulatory approvals and greater collaborative relationships with leading scientists, clinicians and health care professionals in the global asthma community.

Cornerstone and major investor Bruce Mathieson, who asked Mr L'Huillier to chair the new Board in 2014, offered his thanks to the outgoing Board members, Mr L'Huillier and Mr Ribot for their enormous contribution in rebuilding the business and the product offering.

Mr Mathieson said, "Respiri remains strongly positioned with an asthma monitoring system that's ahead of the curve. It has enormous potential to help asthmatics worldwide and over the last four and a half years Leon L'Huillier has steered the progression of the technology with the development of a world-class platform and the next generation breath sensor."

Mr L'Huillier's significant contribution to the Company's development, since his appointment in February 2014, provides the platform from which the Company can grow and thrive. We wish him all the best in his future endeavours.

APPOINTMENTS

The following is a summary of details provided to the Respiri Board by the incoming Directors.

Brendan Mason

A med-tech and China market entry specialist, leading Cochlear Limited (ASX:COH) entry into Greater China as General Manager from 2007 to 2014. Brendan was responsible for market development, sales, marketing, distribution, regulatory affairs, customer support, IP protection and

clinical trials for the Greater China region. He oversaw rapid growth of the business through drivers that required funding and reimbursement, infrastructure development and increasing consumer awareness through managing key opinion leaders and key government stakeholders.

Previously, Brendan worked at Lucent as the Executive Director responsible for Telstra, Lucent's largest account in Asia. He is a past board member, treasurer, and chairman of the Australian Chamber of Commerce, Beijing, where he established the government relations committee to provide advice to Chinese government and Australian member companies.

Brendan Mason is the Non-Executive Director of Australia China Technology Incubator a federal government funded program for MedTech companies who aspire to export.

Brendan is currently CEO and Managing Director of ASX listed SmartTrans Holdings Limited.

Mark Ziirsen

Former Director Finance and IT, Asia Pacific at Cochlear Limited (ASX:COH) and Chief Financial Officer of Admedus Limited (ASX: AHZ). Mark is a highly strategic senior finance leader with proven commercial acumen. He brings to Respiro a strong track record of delivering growth and significant improvement across multiple industry sectors and geographies in executive roles with market leading international organisations. His strong credentials in finance strategy and business performance management are complemented by extensive corporate finance, governance, risk management, strategy, M&A and investor relations skills.

Mark is a Non-Executive Director and Chair of the Audit Committee of ASX listed SmartTrans Holdings Limited.

Chief Executive Officer and Director, Mario Gattino said, "Thanks to the efforts of Leon and John, the Company is now poised with a clear runway to commercialisation with the product launch in Quarter 1 2019. This timing is appropriate to bring new skill sets to the team.

I look forward to working with the newly-appointed directors to bring our much-needed solution to market."

-End-

Contact:

Mario Gattino
CEO & Director
1800 476 632

About Respiri Limited (ASX:RSH)

Respiri is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respiri's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respiri has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respiri products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respiri is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respiri in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies